← Leaderboards
Johnnie Jose Orozco
Fred Hutchinson Cancer Research Center
$5,851,901
Attributed
$6,143,473
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,143,473 · 3
By mechanism
R37$4,715,228 · 1
K01$845,100 · 1
R21$583,145 · 1
Top collaborators
- Christina Marie Termini4 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Brenda Marie Sandmaier$22,185,663
- Oliver W. Press$23,607,906
- Irwin Bernstein$37,471,330
- Brandon K Hadland$2,292,026
- Brian Till$4,139,904
Others in their field
Top investigators on “Bone Marrow”
- Charles A Coltman · Southwest Oncology Group$141,983,231
- Mary M Horowitz · Medical College Of Wisconsin$136,789,389
- David Heimbrook · Leidos Biomedical Research, Inc.$56,049,457
- Richard L Schilsky · University Of Chicago$50,043,295
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$48,148,202
- J. Mark Cline · Wake Forest University$31,844,583
Research focus
Bone MarrowPtprc GeneAntibodiesRadioimmunotherapyAstatineAllogenicRegimenHematologic NeoplasmsInterestRadioisotopesHematopoietic NeoplasmsLeukemiaTransplantationToxic EffectRadiationConditioningOrganHematologyTissuesWhole-Body IrradiationRadiolabeledApoptosisMouse ModelChimerism
Grant awards (16)
Combining Targeted RIT and Synergistic Novel Agent-Renewal$1,329,109
R37 · FY2025 · CA · contact PI
Combining Targeted RIT and Synergistic Novel Agents to Eradicate AML$832,591
R37 · FY2024 · CA · contact PI
Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations$190,863
R21 · FY2024 · CA · contact PI
Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations$89,172
R21 · FY2024 · CA · contact PI
Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations - Admin Supplement$43,297
R21 · FY2024 · CA · contact PI
Combining Targeted RIT and Synergistic Novel Agents to Eradicate AML$841,070
R37 · FY2023 · CA · contact PI
Selective Radionuclide Delivery for Precise Bone Marrow Niche Alterations$259,813
R21 · FY2023 · CA · contact PI
Combining Targeted RIT and Synergistic Novel Agents to Eradicate AML$285,460
R37 · FY2022 · CA · contact PI
Combining Targeted RIT and Synergistic Novel Agents to Eradicate AML$696,694
R37 · FY2021 · CA · contact PI
Combining Targeted RIT and Synergistic Novel Agents to Eradicate AML$1
R37 · FY2021 · CA · contact PI
Combining Targeted RIT and Synergistic Novel Agents to Eradicate AML$730,303
R37 · FY2020 · CA · contact PI
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML$169,020
K01 · FY2019 · CA · contact PI
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML$169,020
K01 · FY2018 · CA · contact PI
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML$169,020
K01 · FY2017 · CA · contact PI
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML$169,020
K01 · FY2016 · CA · contact PI
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML$169,020
K01 · FY2015 · CA · contact PI